GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Net Margin %

Nymox Pharmaceutical (Nymox Pharmaceutical) Net Margin % : 0.00% (As of Sep. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Nymox Pharmaceutical's Net Income for the three months ended in Sep. 2023 was $-1.04 Mil. Nymox Pharmaceutical's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Nymox Pharmaceutical's net margin for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for Nymox Pharmaceutical's Net Margin % or its related term are showing as below:

NYMXF' s Net Margin % Range Over the Past 10 Years
Min: -234760   Med: -4079.67   Max: 97440
Current: 97440


NYMXF's Net Margin % is ranked better than
99.81% of 1030 companies
in the Biotechnology industry
Industry Median: -157.59 vs NYMXF: 97440.00

Nymox Pharmaceutical Net Margin % Historical Data

The historical data trend for Nymox Pharmaceutical's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Net Margin % Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,543.14 -11,346.55 -234,760.00 - -

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 26,780.00 - - -

Competitive Comparison of Nymox Pharmaceutical's Net Margin %

For the Biotechnology subindustry, Nymox Pharmaceutical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Net Margin % falls into.



Nymox Pharmaceutical Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nymox Pharmaceutical's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-6.576/0
= %

Nymox Pharmaceutical's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin=Net Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-1.036/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical  (OTCPK:NYMXF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Nymox Pharmaceutical Net Margin % Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-02-2022

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

NYMOX Receives RTF letter from FDA

By PurpleRose PurpleRose 07-12-2022

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022

NYMOX Updates Shareholders

By PurpleRose PurpleRose 07-15-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-22-2022

Nymox Provides Current Update

By sperokesalga sperokesalga 05-10-2023